Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 9Carcinoma, Renal Cell 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Kidney Neoplasms 3Lymphoma 2Leukemia 2Skin Neoplasms 1Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Ovarian Neoplasms 1Osteosarcoma 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neurofibroma 1Neoplasms 1Neoplasm Metastasis 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Leukemia-Lymphoma, Adult T-Cell 1HTLV-I Infections 1Glioma 1Fallopian Tube Neoplasms 1Cholangiocarcinoma 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

mirdametinib 2tipifarnib 1peginterferon alfa-2b 1nilotinib 1binimetinib 1Vincristine 1Temozolomide 1Radiosurgery 1Imatinib Mesylate 1Everolimus 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neurofibroma × peginterferon alfa-2b × Clear all
NCT00846430 2023-08-30

Medical Treatment of "High-Risk" Neurofibromas

Corewell Health West

Phase 2 Completed
9 enrolled 9 charts
CNS

Neurofibroma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡